Rx-to-OTC switch, meeting demand for more natural OTC products and expanding in emerging markets will help GlaxoSmithKline’s standalone consumer health business grow faster than the market when it launches later this year, according to CEO designate Brian McNamara.
Speaking at GSK’s capital markets day, McNamara said the standalone business – which will be called Haleon – was expected to deliver organic annual sales growth of 4-6% over the medium term
Haleon will demerge from GSK in July, the company confirmed, and be listed in London and New York